Want to see GB:APTA full AI Analyst Report?
Top Page
Aptamer Group Plc
(LSE:APTA)
Select Model
Select Model
Rating:43Neutral
Price Target:
0.31 p
▼(-10.29% Downside)
Action:Upgraded
Date:10/15/26
The score is held down primarily by persistent operating losses and ongoing cash burn despite improving margins, while a strengthened, low-debt balance sheet provides some stability. Technically, the stock remains in a broader downtrend with weak momentum, and valuation is constrained by negative earnings and no stated dividend yield.
Positive Factors
Revenue rebound
The return to revenue growth after weakness through 2024 indicates some stabilization in customer demand and commercial activity. If maintained, a larger revenue base could improve operating leverage, support investment in aptamer development, and help the company progress toward sustainable scale.
Negative Factors
Persistent deep losses
Profitability remains the central fundamental weakness because operating costs are still far above the revenue base. Continued deep losses limit internally generated funding, weaken returns on capital, and make progress toward a self-sustaining business dependent on substantial improvement in scale or cost control.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The return to revenue growth after weakness through 2024 indicates some stabilization in customer demand and commercial activity. If maintained, a larger revenue base could improve operating leverage, support investment in aptamer development, and help the company progress toward sustainable scale.
Read all positive factors
Aptamer Group Plc (APTA) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£10.23M
Dividend YieldN/A
Average Volume (3M)3.87M
Price to Earnings (P/E)―
Beta (1Y)0.34
Revenue Growth28.35%
EPS Growth57.14%
CountryUK
Employees34
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding3,468,080,600
10 Day Avg. Volume3,529,869
30 Day Avg. Volume3,873,358
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)2.48
Price to Sales (P/S)9.21
P/FCF Ratio-6.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aptamer Group Plc Business Overview & Revenue Model
Company Description
Aptamer Group plc, an international company headquartered in York, United Kingdom, specializes in providing advanced binders for applications spanning research, diagnostics, and therapeutics. Their innovative binder technology is engineered to res...
Aptamer Group Plc Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
62
Positive
Cash Flow
38
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.54M | 1.20M | 860.00K | 1.75M | 4.04M |
| Gross Profit | 573.00K | 350.00K | 250.00K | 359.00K | 2.69M |
| EBITDA | -2.60M | -2.28M | -2.81M | -7.36M | -2.20M |
| Net Income | -1.86M | -2.42M | -2.96M | -7.84M | -2.09M |
Balance Sheet | |||||
| Total Assets | 7.18M | 2.83M | 2.77M | 2.75M | 11.52M |
| Cash, Cash Equivalents and Short-Term Investments | 4.36M | 1.06M | 870.00K | 234.00K | 6.69M |
| Total Debt | 170.00K | 491.00K | 817.00K | 1.08M | 1.31M |
| Total Liabilities | 1.44M | 1.45M | 1.88M | 2.45M | 3.47M |
| Stockholders Equity | 5.74M | 1.38M | 887.00K | 304.00K | 8.05M |
Cash Flow | |||||
| Free Cash Flow | -2.30M | -2.01M | -2.41M | -6.09M | -2.79M |
| Operating Cash Flow | -2.13M | -2.00M | -2.28M | -4.06M | -2.38M |
| Investing Cash Flow | -253.00K | -92.00K | -122.00K | -2.03M | -418.00K |
| Financing Cash Flow | 5.68M | 2.28M | 3.04M | -365.00K | 9.12M |
Aptamer Group Plc Technical Analysis
Negative
0.35
Price Trends
0.33
Negative
0.40
Negative
0.56
Negative
Market Momentum
>-0.01
Positive
26.62
Positive
28.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:APTA, the sentiment is Negative. The current price of 0.35 is above the 20-day moving average (MA) of 0.32, above the 50-day MA of 0.33, and below the 200-day MA of 0.56, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 26.62 is Positive, neither overbought nor oversold. The STOCH value of 28.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:APTA.
Aptamer Group Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
89 Outperform | £104.50M | 13.79 | 67.81% | 7.50% | -1.10% | 0.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £37.37M | 165.00 | 3.75% | ― | ― | ― | |
43 Neutral | £10.23M | -9.83 | -46.61% | ― | 28.35% | 57.14% | |
43 Neutral | £294.51M | -6.63 | -1293.07% | ― | ― | ― | |
43 Neutral | £7.51M | -6.06 | -97.87% | ― | 7.38% | 44.13% | |
40 Underperform | £14.45M | -0.27 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:APTA
Aptamer Group Plc
0.30
-0.52
-64.02%
GB:AVCT
Avacta Group plc
60.50
-9.50
-13.57%
GB:BVXP
Bioventix
2,000.00
98.30
5.17%
GB:OBD
Oxford BioDynamics
0.11
-0.21
-66.56%
GB:FAB
Fusion Antibodies Plc
6.00
-7.50
-55.56%
GB:AREC
Arecor Therapeutics PLC
82.50
11.00
15.38%
Aptamer Group Plc Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Aptamer Group lifts revenue and cash as licensing and pharma demand deepen
Positive
Oct 13, 2026
Aptamer Group reported full-year revenue of £1.5 million, up 28% year-on-year, supported by growing demand for its Optimer technology and repeat work with multiple top 20 pharmaceutical companies. A £4.1 million equity raise lifted the y...
Business Operations and StrategyFinancial Disclosures
Aptamer Group Sets Analyst and Investor Meetings for Full-Year Results
Positive
Oct 7, 2026
Aptamer Group plc plans to release its full-year results for the period ended 30 June 2026 on 13 October, alongside a scheduled online briefing for analysts hosted by Chief Executive Dr Arron Tolley and Chief Financial Officer Andrew Rapson. The c...
Business Operations and Strategy
Aptamer Group Adds Cavendish as Joint Corporate Broker to Bolster Investor Reach
Positive
Aug 20, 2026
Aptamer Group plc has appointed Cavendish Capital Markets as joint corporate broker alongside Turner Pope Investments, strengthening its capital markets advisory team. The move aims to expand research coverage and deepen institutional engagement a...
Business Operations and StrategyExecutive/Board Changes
Aptamer Group boosts director stakes and launches major incentive scheme
Positive
Aug 14, 2026
Aptamer Group has issued 12,936,511 new ordinary shares to remunerate Non-Executive Chairman Adam Hargreaves, via Pathcelerate Limited, and Non-Executive Director Tim Sykes, for services during the year to 30 June 2026. The share-based payments li...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.